Skip to main content
SpringerLink
Log in

Immune-related AEs associated with outcomes during dual ICI therapy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma Targeted Oncology : 26 Dec 2022. Available from: URL: https://doi.org/10.1007/s11523-022-00940-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immune-related AEs associated with outcomes during dual ICI therapy. Reactions Weekly 1940, 10 (2023). https://doi.org/10.1007/s40278-023-31868-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-31868-1

Search

Navigation